Navigation Links
An Animal-Free DNase I


Digestion of DNA to undetectable levels is important in many molecular biology applications. For instance, accurate quantitation of RNA targets by RT-PCR requires the removal of contaminating genomic DNA targets. In vitro transcribed RNA is also frequently treated with DNase to remove template DNA in both research and pharmaceutical applications. Ambion now supplies a recombinant DNase I that is prepared in a host with little to no RNase activity. The host is non-animal derived and the enzyme is purified through a process devoid of any animal byproducts.


Isolating RNase-free DNase I is a Challenge
DNase I has historically been prepared from bovine pancreas, one of the richest sources of RNase activity (~1 mg RNase A per gram of tissue). Therefore, it is often hard to obtain DNase I sufficiently free of RNase that it will not compromise RNA analysis experiments. Providing a high quality, RNase-free DNase I is very important to Ambion. This is borne out in a recent Biotechniques article (Matthews et al, 2002) that compared several different manufacturer's DNase I products (see sidebar at right).


A Pure Source of DNase I
Ambion employs stringent purification protocols and qualifies our bovine-derived DNase I at concentrations 5X or greater than that recommended for use. Now Ambion goes a step further by providing an alternative to bovine DNase I, recombinant DNase I (rDNase I), that further eliminates residual RNase and other copurified contaminants. rDNase is a highly purified product derived from cloned bovine DNase I. The rDNase I is prepared in a host that has RNase levels that are 1 x 107 fold lower than bovine pancreas.

Safety of biological products is also an emerging issue. Eliminating animal tissues and animal-derived components from the production process prevents potential transmission of pathogens. Materials derived from bovine sources are of special concern, due to known transmission of bovine spongiform encephalopathy (BSE) to humans via ingestion of cow products. Regulatory agencies are increasingly restrictive in this regard, prompting the pharmaceutical industry to remove high risk raw materials from manufacturing. Ambion's rDNase I now addresses these issues by providing a recombinant replacement for pancreatic bovine DNase I.


rDNase I Performance
Ambion's rDNase I meets or exceeds the performance of native bovine DNase I. It digests DNA to oligonucleotide-sized products or shorter. Yet its reaction kinetics are identical to that of native DNase I. Thus, rDNase I can be directly substituted for native DNase I with equivalent units.

The recommended reaction conditions are the same as Ambion's standard DNase I. Incubate 1-2 U of rDNase I per 1 g DNA for 30 min at 37C in a buffer consisting of 10 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 0.5 mM CaCl2.


Quantitative Removal of Contaminating DNA
To demonstrate the efficiency of rDNase I in removing residual DNA, we measured genomic DNA contamination by real-time PCR before and after DNase I treatment. A total of 0.5 g of human genomic DNA was incubated in 50 l, and digested with 2 U of DNase I or rDNase I in a volume of 50 l for 30 min at 37C. One-tenth of this reaction volume (equivalent to 50 ng genomic DNA) was added to a 25 l real-time PCR reaction. The efficiency of DNA degradation was monitored by comparing cycle thresholds (Ct), with and without DNase digestion. As shown in Figure 1B, both DNase I and rDNase I shifted the real-time PCR signal by an average of 13.4 Ct's, or about 11,000-fold, to less than a single copy genome equivalent (~2 pg genomic DNA).

Figure 1. Real-time PCR of Genomic DNA Samples Treated with rDNase I vs. Bovine Pancreatic DNase I. (A) Standard curve generated with 10 fold serial dilutions of human genomic DNA ranging from 100 ng to 10 pg using an ABI 7900 real-time PCR machine. The target amplified was human GAPDH. (B) GAPDH was amplified from three human genomic DNA samples (0.5 g), either treated with DNase I (Ct=36.1), treated with rDNase I (Ct =36.9), or untreated (Ct= 23.1). The two DNase I treatments gave essentially identical results and were therefore averaged and compared to the untreated sample. The Ct of the averaged DNase I treatments vs. untreated human genomic DNA was 13.4.


Lack of RNase Activity
Since rDNase I is derived from a substantially "cleaner" source than pancreatic DNase I, the enzyme can be more readily purified to a RNase-free state. Although the recommended usage conditions for DNase I rarely require more than 2U per reaction, rDNase I passes Ambion's stringent RNase contamination quality control assay using 10 times as much enzyme for a 32-fold longer incubation! This result means that rDNase I is qualified RNase-free at 320 times typical usage conditions, creating an unsurpassed margin of safety for every application.


back to top


Ordering Information
For prices and availability, please contact our Customer Service Department.
Cat# Product Name Size 2235 Recombinant DNase I (RNase-free) 1000 U
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. The Worlds Best DNase Improved TURBO DNA-free
2. TURBO DNase: Hyperactive, Salt Tolerant DNase
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Animal Free DNase

(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), a leading ... pharmaceutical and biotech industry, has announced that Dr. Mark ... of Director of Science & Technology. , “Mark brings ... drug metabolism and bioanalysis to EZVS in both pharma ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... "Quantum Man: Richard Feynman,s Life in Science," ASU Foundation Professor and ... a legendary and sometimes very public modern physicist, has been chosen ... in the UK. Feynman is one of the most ... he did much to bring science to the people, taking time ...
... Technologies, a global provider of comprehensive scientific management solutions, ... industry, is pleased to announce the company has donated ... Susan G. Komen for the Cure ® Tissue ... donation was presented to the Komen Tissue Bank on ...
... Dec. 21, 2011 Acumen Pharmaceuticals announces today ... (formerly Merck & Co., Inc.) of a 2003 ... Merck exclusive worldwide rights to develop and commercialize ... Merck,s decision to discontinue this ...
Cached Biology Technology:Book on Richard Feynman nets honors for Arizona State professor 2Book on Richard Feynman nets honors for Arizona State professor 3BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 2BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 3Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck 2
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia ... the human genome which can explain why some white blood ... multiple sclerosis (MS). This is the first study to look ... responsible for the devastation caused by MS. The broad-based study ...
... (Sept. 3, 2013) Clay, an abundant and cheap natural ... operate at very high temperatures, according to Rice University researchers ... of materials scientist Pulickel Ajayan reported today in Nature,s online ... at temperatures of up to 200 degrees Celsius (392 degrees ...
... Mass grave detection . . . ... gain closure, and killers may receive appropriate punishment, because ... graves. While investigators can find some graves, perhaps hundreds ... Tennessee,s Forensic Anthropology Center and Oak Ridge National Laboratory ...
Cached Biology News:First study to investigate the human genome in multiple sclerosis 2Clay key to high-temperature supercapacitors 2Clay key to high-temperature supercapacitors 3September 2013 story tips 2September 2013 story tips 3
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: